Is alcohol ablation of the septum associated with recurrent tachyarrhythmias?

Swiss Medical Weekly

Volumn 137, Issue 47-48, 2007, Pages 660-668

  Streit, Sven ^a   Walpoth, Nazan ^a   Windecker, Stephan ^a   Meier, Bernhard ^a   Hess, Otto ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b BERN UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Alcohol ablation; Hypertrophic cardiomyopathy; Tachyarrhythmias

Indexed keywords

ALCOHOL;

ADULT; AGED; ARTICLE; BRADYCARDIA; CATHETER ABLATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART INFARCTION; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE SEPTUM; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; PACEMAKER; RECURRENT DISEASE; SUDDEN DEATH;

EID: 36849065198     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Chien KR. Genomic circuits and the integrative biology of cardiomyopathies. Eur Heart J. 2001;3:L3-9.
2. Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232-9.
3. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. The Lancet. 1995;346:211-4.
4. Kuhn H, Gietzen F, Leuner C, Gerenkamp T. Induction of subaorticseptal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy. Eur Heart J. 1997;18:846-51.
5. Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-months follow-up in 25 patients. J Am Coll Cardiol. 1998;31:252-8.
6. Faber L, Seggewiss H, Welge D, Fassbender D, Schmidth HK, Gleichmann U, et al. Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience. Eur J Echocardiography. 2004;5:347-55.
7. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young adults. J Am Coll Cardiol. 2003;42:873-9.
8. Xin J, Shiota T, Lever HM, Kapadia SR, Sitges M, Rubin DN, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery. J Am Coll Cardiol. 2001;38:1994-2000.
9. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Role of transcoronary ablation of septal hypertrophy in patients with hypertrophic cardiomyopathy, New York Heart Association functional class III or IV, and outflow obstruction only under provocable conditions. Circulation. 2002;106:454-9.
10. Seggewiss H. Current status of alcohol septal ablation for patients with hypertrophic obstructive cardiomyopathy. Curr Cardiol Rep. 2001;3:160-6.
11. Veselka J, Procházková S, Duchonová R, et al. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: lower alcohol dose reduces size of infarction and has comparable hemodynamic and clinical out-come. Catheter Cardiovasc Interv. 2004;63:231-5.
12. Veselka J, Duchonová R, Procházková S, et al. Effects of varying ethanol dosing in percutaneous septal ablation for obstructive hypertrophic cardiomyopathy on early hemodynamic changes. Am J Cardiol. 2005;95:675-8.
13. Hess OM, Krayenbuehl HP. Management of hypertrophic cardiomyopathy. Curr Opin Cardiol. 1993;8:434-40.
14. Firoozi S, Elliott PM, Sharma S, Murday A, Brecker SJ, Hamid MS, et al. Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy. Eur Heart J. 2002;23:1617-24.
15. Nagueh SF, Ommen SR, Lakkis NM, Killip D, Zoghbi WA, Schaff HV, et al. Comparison of ethanol septal reduction therapy with surgical myectomy for the treatment of hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001;38:1701-6.
16. Chang SM, Nagueh SF, Spencer WH 3rd, Lakkis NM. Complete heart block: determinants and clinical impact in patients with hypertrophic obstructive cardiomyopathy undergoing nonsurgical septal reduction therapy. J Am Coll Cardiol. 2003;42:296-300.
17. Osterne EC, Seixas TN, Paulo Filho W, Osterne EM, Gomes OM. Percutaneous transluminal septal alcoholization for the treatment of refractory hypertrophic obstructive cardiomyopathy: initial experience in the Federal District. Arq Bras Cardiol. 2003;80:359-78.
18. Chang SM, Lakkis NM, Franklin J, Spencer WH 3rd, Nagueh SF. Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy. Circulation. 2004;109:824-7.
19. Gietzen FH, Leuner CJ, Obergassel L, Strunk-Mueller C, Kuhn H. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients. Heart. 2004;90:638-44.
20. Talreja DR, Nishimura RA, Edwards WD, Valeti US, Ommen SR, Tajik AJ, et al. Alcohol septal ablation versus surgical septal myectomy: comparison of effects on atrioventricular conduction tissue. J Am Coll Cardiol. 2004;44:2329-32.
21. Faber L, Seggewiss H, Gietzen FH, Kuhn H, Boekstegers P, Neuhaus L, et al. Catheter-based septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: Follow-up results of the TASH-registry of the German Cardiac Society. Z Kardiol. 2005;94:516-23.
22. Fernandes VL, Nagueh SF, Wang W, Roberts R, Spencer WH 3rd. A prospective follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy - the Baylor experience (1996-2002). Clin Cardiol. 2005;28:124-30.
23. Cohn LH, Trehan H, Collins JJ Jr. Long-term follow-up of patients undergoing myotomy/myectomy for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1992;70:657-60.
24. Ten Berg JM, Suttorp MJ, Knaepen PJ, Ernst SM, Vermeulen FE, Jaarsma W. Hypertrophic obstructive cardiomyopathy. Initial results and long-term follow-up after Morrow septal myectomy. Circulation. 1995;91:2499-500.
25. Schönbeck MH, Brunner-La Rocca HP, Vogt PR, Lachat ML, Jenni R, Hess OM, et al. Long-Term Follow-up in Hypertrophic Obstructive Cardiomyopathy After Septal Myectomy. Ann Thorac Surg. 1998;65:1207-14.
26. Minami K, Boethig D, Woltersdorf H, Seifert D, Körfer R. Long term follow-up of surgical treatment of hypertrophic obstructive cardiomyopathy (HOCM): the role of concomitant cardiac procedures. Eur J Cardiothorac Surg. 2002;22:206-10.
27. Castedo E, Cabo RA, Nunez I, Monguio E, Montero CG, Burgos R, et al. Surgical treatment for hypertrophic obstructive cardiomyopathy. Rev Esp Cardiol. 2004;57:751-6.
28. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:470-6.
29. Faber L, Welge D, Fassbender D, Schmidt HK, Horstkotte D, Seggewiss H. Percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: Managing the risk of procedure-related AV conduction disturbances. Int J Cardiol. 2007;119:163-7.
30. Elliott PM, Gimeno JR, Tomé MT, Shah J, Ward D, Thaman JM, et al. Left Ventricular outflow tract obstruction and sudden cardiac death risk in patients with hypertrophic cardiomyopathy. Eu Heart J. 2006;27:1933-41.
31. Maron BJ. Role of alcohol septal ablation in treatment of obstructive hypertrophic cardiomyopathy. Lancet. 2000;355:425-6.
32. Mahboob A, Hisham D, Nasser L. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A Systematic Review of Published Studies. J Intervent Cardiol. 2006;19:319-27.
33. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004;109:452-6.
34. Veselka J. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A review of the literature. Med Sci Monit. 2007;13:RA62-68.
35. Maron BJ. New interventions for obstructive hypertrophic cardiomyopathy: promise and prudence. Eur Heart J. 1999;20:1292-4.